文献速递消化系统肿瘤

cGAS-STING通路基因变异预测转移性结直肠癌患者预后:FIRE-3与TRIBE试验数据

Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
PubMed 文献 · Eur J Cancer · 2022-06-21

研究对FIRE-3和TRIBE试验中转移性结直肠癌患者的血液DNA进行基因分型,分析cGAS-STING通路7个单核苷酸多态性与生存的关系。在西妥昔单抗队列中,STING rs1131769携带任何T等位基因者总生存显著缩短,IFNB1 rs1051922 G/A和A/A基因型者无进展生存显著缩短;这些关联在贝伐珠单抗队列中未观察到。

要点

  • 西妥昔单抗队列中,STING rs1131769任何T等位基因者总生存较C/C携带者显著缩短(36.3 vs 56.1个月)。
  • 西妥昔单抗队列中,IFNB1 rs1051922 G/A和A/A基因型者无进展生存较G/G携带者显著缩短。
  • 上述关联在FIRE-3和TRIBE的贝伐珠单抗队列中均未观察到。

核心结论

  • STING和IFNB1基因的胚系多态性可能预测转移性结直肠癌患者基于西妥昔单抗治疗的结局。

研究设计与样本

  • 对FIRE-3试验(西妥昔单抗组n=129;贝伐珠单抗组n=107)和TRIBE试验(贝伐珠单抗组n=215)入组患者血液样本的基因组DNA,使用OncoArray-500K bead chip芯片进行基因分型。
  • 分析cGAS、STING和IFNB1三个基因中7个选定单核苷酸多态性与总生存和无进展生存的关联。

主要发现

  • 西妥昔单抗队列中,STING rs1131769任何T等位基因携带者总生存较C/C携带者显著缩短(36.3 vs 56.1个月),单因素分析HR=2.08(95%CI 1.06-4.07,P=0.03),多因素分析HR=2.98(95%CI 1.35-6.6,P=0.0085)。
  • 西妥昔单抗队列中,IFNB1 rs1051922 G/A和A/A基因型携带者无进展生存较G/G携带者显著缩短:单因素分析G/A vs G/G为10.2 vs 14.1个月,HR=1.84(95%CI 1.23-2.76);A/A vs G/G为10.7 vs 14.1个月,HR=2.19(95%CI 0.97-4.96),P=0.0077;多因素分析G/A vs G/G HR=2(95%CI 1.22-3.3),A/A vs G/G HR=2.19(95%CI 0.92-5.26),P=0.02。
  • 上述关联在FIRE-3或TRIBE的贝伐珠单抗队列中未观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The activation of stimulator of interferon genes (STING) was reported to enhance cetuximab-mediated natural killer cell activation and dendritic cell maturation. Polymorphisms in genes in the cyclic GMP-AMP synthase (cGAS)-STING pathway may affect innate immune response. Therefore, we hypothesised that genetic variants in the cGAS-STING pathway may predict the efficacy of cetuximab-based treatment in patients with metastatic colorectal cancer. METHODS: Genomic DNA from blood samples of patients enrolled in FIRE-3 (cetuximab arm, n = 129; bevacizumab arm, n = 107) and TRIBE (bevacizumab arm, n = 215) was genotyped using the OncoArray-500K bead chip panel. Seven selected single nucleotide polymorphisms in 3 genes (cGAS, STING and interferon B1 (IFNB1)) were analysed for the association with overall survival and progression-free survival. RESULTS: In the cetuximab cohort, patients with STING rs1131769 any T allele showed significantly shorter overall survival (36.3 versus 56.1 months) than carriers of C/C in both univariate [hazard ratio (HR) = 2.08; 95% confidence interval (CI): 1.06-4.07; P = 0.03] and multivariate (HR = 2.98; 95% CI: 1.35-6.6; P = 0.0085) analyses; patients carrying IFNB1 rs1051922 G/A and A/A genotype showed a significantly shorter progression-free survival than carriers of G/G allele in both univariate (G/A versus G/G, 10.2 versus 14.1 months, HR = 1.84; 95% CI 1.23-2.76; A/A versus G/G, 10.7 versus 14.1 months, HR = 2.19; 95% CI 0.97-4.96; P = 0.0077) and multivariate analyses (G/A versus G/G, HR = 2; 95% CI 1.22-3.3; A/A versus G/G, HR = 2.19, 95% CI 0.92-5.26, P = 0.02). These associations were not observed in the bevacizumab arm of FIRE-3 or TRIBE. CONCLUSION: These results suggest for the first time that germline polymorphisms in STING and IFNB1 genes may predict the outcomes of cetuximab-based treatment in patients with metastatic colorectal cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang J, Xiao Y, Loupakis F, et al. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. Eur J Cancer. 2022. PMID: 35749909. doi:10.1016/j.ejca.2022.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。